Microencapsulation specialist Micap has made its first foray into
the pharmaceutical sector after clinching a licensing deal with UK
drug delivery specialist SkyePharma.
Dutch drug delivery company OctoPlus will undergo a significant
change in 2004 as it completes its transformation from a
formulation services company to one firmly planted in drug
development.
Japanese pharmaceutical companies must build strong, in-house,
R&D capabilities in order to survive, according to research
from market analyst firm Datamonitor. But this is not simply a
matter of spending more money; strategic...
Chiltern International, one of Europe's leading mid-sized contract
research organisations, has opened up an office in Ukraine to tap
into a growing market for clinical trial services in central and
Eastern Europe.
European clinical researchers have launched a campaign calling on
the European Parliament and Commission to repeal a new Directive on
Good Clinical Practice (GCP) on the grounds that it will hinder the
conduct of non-commercial trials.
Chemical Synthesis Services has opened a new, £25 million (€36
million) facility in Craigavon, Northern Ireland, improving its
drug development and analysis services.
Leading CRO says it has seen a marked increase in the number of
trials it has been asked to work on in Central Europe, and believes
the trend is set to continue.
Transgenic plant technologies could lead to a revolution in vaccine
production and manufacture; should plant-based vaccines prove
effective in clinical trials, this will drive licensing activity
between key vaccine players and companies...
Bristol-Myers Squibb has filed an IND in the US seeking approval to
start clinical trials of an orally-active p38 MAP kinase inhibitor
for rheumatoid arthritis.
The genomics industry is already separating into two tiers; the
winners are those focused on targets and drug development and which
have products in or near the clinic, as well as strong
partnerships, says analyst
Argonaut sells its HPLC business to Grace Vydac as it refocuses on
supplying consumables for companies working on drug discovery.
Reports reduced losses in first half.
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
KS Avicenna, the Canadian unit of KS Biomedix of the UK, launched a
newly expanded contract biopharmaceutical manufacturing facility in
Canada, to service both North American and European clients, at the
start of the BIO 2003 meeting,...
There has been a steady increase in the number of diabetes-related
R&D projects in recent years, and one area of particular
interest is the pulmonary delivery of insulin, says a new report